148 related articles for article (PubMed ID: 28844708)
1. Osteopontin and their roles in hematological malignancies: Splice variants on the new avenues.
Bastos ACSF; Blunck CB; Emerenciano M; Gimba ERP
Cancer Lett; 2017 Nov; 408():138-143. PubMed ID: 28844708
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
3. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin splice variants and polymorphisms in cancer progression and prognosis.
Briones-Orta MA; Avendaño-Vázquez SE; Aparicio-Bautista DI; Coombes JD; Weber GF; Syn WK
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):93-108.A. PubMed ID: 28254527
[TBL] [Abstract][Full Text] [Related]
5. The Intracellular and Secreted Sides of Osteopontin and Their Putative Physiopathological Roles.
Bastos ACSDF; Gomes AVP; Silva GR; Emerenciano M; Ferreira LB; Gimba ERP
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769264
[TBL] [Abstract][Full Text] [Related]
6. Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review).
Gimba ERP; Brum MCM; Nestal De Moraes G
Int J Oncol; 2019 Feb; 54(2):420-430. PubMed ID: 30535434
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin: its potential role in cancer of children and young adults.
Karpinsky G; Fatyga A; Krawczyk MA; Chamera M; Sande N; Szmyd D; Izycka-Swieszewska E; Bien E
Biomark Med; 2017 Apr; 11(4):389-402. PubMed ID: 28326824
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer.
Tang X; Li J; Yu B; Su L; Yu Y; Yan M; Liu B; Zhu Z
Int J Biol Sci; 2013; 9(1):55-66. PubMed ID: 23289017
[TBL] [Abstract][Full Text] [Related]
9. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways.
Gimba ER; Tilli TM
Cancer Lett; 2013 Apr; 331(1):11-7. PubMed ID: 23246372
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
Nakamura KD; Tilli TM; Wanderley JL; Palumbo A; Mattos RM; Ferreira AC; Klumb CE; Nasciutti LE; Gimba ER
Tumour Biol; 2016 Feb; 37(2):2655-63. PubMed ID: 26404131
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior.
Ferreira LB; Tavares C; Pestana A; Pereira CL; Eloy C; Pinto MT; Castro P; Batista R; Rios E; Sobrinho-Simões M; Gimba ER; Soares P
Oncotarget; 2016 Aug; 7(32):52003-52016. PubMed ID: 27409830
[TBL] [Abstract][Full Text] [Related]
12. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.
Hahnel A; Wichmann H; Greither T; Kappler M; Würl P; Kotzsch M; Taubert H; Vordermark D; Bache M
BMC Cancer; 2012 Apr; 12():131. PubMed ID: 22471890
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.
Silva GR; Mattos DS; Bastos ACF; Viana BPPB; Brum MCM; Ferreira LB; Gimba ERP
Mol Biol Rep; 2020 Oct; 47(10):8339-8345. PubMed ID: 33006711
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1.
Sun J; Feng A; Chen S; Zhang Y; Xie Q; Yang M; Shao Q; Liu J; Yang Q; Kong B; Qu X
Cell Mol Immunol; 2013 Mar; 10(2):176-82. PubMed ID: 23416968
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance.
Mirzaei A; Mohammadi S; Ghaffari SH; Yaghmaie M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Asian Pac J Cancer Prev; 2018 Mar; 19(3):615-623. PubMed ID: 29580029
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis.
Hao C; Wang Z; Gu Y; Jiang WG; Cheng S
Biomed Res Int; 2016; 2016():7310694. PubMed ID: 27462610
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin-c splicing isoform contributes to ovarian cancer progression.
Tilli TM; Franco VF; Robbs BK; Wanderley JL; da Silva FR; de Mello KD; Viola JP; Weber GF; Gimba ER
Mol Cancer Res; 2011 Mar; 9(3):280-93. PubMed ID: 21263033
[TBL] [Abstract][Full Text] [Related]
19. Expression of osteopontin-5 splice variant in the mouse primary and metastatic breast cancer cells.
Kamalabadi-Farahani M; Atashi A; Jabbarpour Z; Aghayan SS
BMC Res Notes; 2022 Sep; 15(1):286. PubMed ID: 36064446
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin as a therapeutic target for cancer.
Bandopadhyay M; Bulbule A; Butti R; Chakraborty G; Ghorpade P; Ghosh P; Gorain M; Kale S; Kumar D; Kumar S; Totakura KV; Roy G; Sharma P; Shetti D; Soundararajan G; Thorat D; Tomar D; Nalukurthi R; Raja R; Mishra R; Yadav AS; Kundu GC
Expert Opin Ther Targets; 2014 Aug; 18(8):883-95. PubMed ID: 24899149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
